liver cancer
![HistoSonics, histotripsy technology, liver cancer, de novo clearance, ultrasound](https://pharmtales.com/wp-content/uploads/2023/10/HistoSonics-receives-FDA-approval-for-its-ultrasound-device-that-destroys-liver-tumors-without-surgery.jpg)
HistoSonics receives FDA approval for its ultrasound device that destroys liver tumors without surgery
In a groundbreaking move, the FDA has granted clearance to histotripsy technology, marking a significant milestone for HistoSonics and its ...
![Tecentriq, Roche, Immunotherapy, PD-L1 inhibitor, lung cancer, bladder cancer, breast cancer, liver cancer](https://pharmtales.com/wp-content/uploads/2023/08/Tecentriq-SC-A-Swift-Leap-Forward-in-Cancer-Treatment-Receives-Green-Light.jpg)
Tecentriq SC: A Swift Leap Forward in Cancer Treatment Receives Green Light
Roche has proudly unveiled that Tecentriq SC (atezolizumab) has received the stamp of approval from the Medicines and Healthcare products ...
![Elevar Therapeutics, Rivoceranib-Camrelizumab, Liver Cancer, FDA](https://pharmtales.com/wp-content/uploads/2023/07/Elevar-Therapeutics-Announces-FDA-Acceptance-of-Rivoceranib-Camrelizumab-Combo-for-Liver-Cancer.jpg)
Elevar Therapeutics Announces FDA Acceptance of Rivoceranib-Camrelizumab Combo for Liver Cancer
On July 17, 2023Ā Elevar Therapeutics, a fully integrated biopharmaceutical company focused on improving treatment options for patients with limited ...
![Imfinzi + Imjudo Unprecedented 4-Year Survival in Advanced Liver Cancer | Pharmtales](https://pharmtales.com/wp-content/uploads/2023/07/Imfinzi-Imjudo-Unprecedented-4-Year-Survival-in-Advanced-Liver-Cancer.jpg)
Imfinzi + Imjudo: Unprecedented 4-Year Survival in Advanced Liver Cancer
Source – AstraZeneca On 29 June 2023, new findings from the HIMALAYA Phase III trial revealed that AstraZeneca’s Imfinzi (durvalumab) ...
![FDA accepts Merck's application for Keytruda plus chemo in liver cancer](https://pharmtales.com/wp-content/uploads/2023/06/FDA-accepts-Mercks-application-for-Keytruda-plus-chemo-in-liver-cancer.jpg)
FDA accepts Merck’s application for Keytruda plus chemo in liver cancer
The FDA has granted acceptance to Merck’s application for the popular drug Keytruda, in combination with standard-of-care chemotherapy (gemcitabine plus ...